Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06651151 | NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma(NeoLIPA) | recruiting | Phase 2 | 27 | Oslo University HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04091217 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Oct 24, 2024 |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03776136 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | completed | Phase 2 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 9, 2024 | clinicaltrials |
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02027935 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT00863330 | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | terminated | Phase 2 | 1 | Ralph HaukeOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT03200847 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 1 / Phase 2 | 26 | University of Colorado, DenverOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | withdrawn | Phase 2 | 0 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | completed | Phase 1 / Phase 2 | 24 | Lokon Pharma ABINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | terminated | Phase 2 | 4 | Providence Health & ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | terminated | Phase 2 | 15 | Karyopharm Therapeutics IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT01256359 | Docetaxel With or Without AZD6244 in Melanoma(DOC-MEK) | completed | Phase 2 | 83 | University of OxfordOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04951583 | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma(FMT-LUMINATE) | unknown | Phase 2 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT01894672 | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06500091 | TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | not yet recruiting | Phase 2 | 54 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02981303 | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | completed | Phase 2 | 64 | HiberCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04924413 | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | terminated | Phase 2 | 9 | Quanli GaoOTHER_GOV | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06470880 | Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy(DyNAMIc) | not yet recruiting | Phase 2 | 40 | The Christie NHS Foundation TrustOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT03484923 | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma(PLATforM) | completed | Phase 2 | 196 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 18, 2024 | clinicaltrials |
| NCT02631447 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study(SECOMBIT) | completed | Phase 2 | 251 | Fondazione Melanoma OnlusOTHER | 10 | Jun 7, 2024 | clinicaltrials |
| NCT01119508 | Ipilimumab + Temozolomide in Metastatic Melanoma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma(QUAD01) | terminated | Phase 1 / Phase 2 | 2 | Jason J. Luke, MDOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02107755 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | completed | Phase 1 / Phase 2 | 217 | AmgenINDUSTRY | 3 | May 14, 2024 | clinicaltrials |
| NCT02621515 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases(CA209-322) | terminated | Phase 2 | 7 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00199342 | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | recruiting | Phase 2 | 28 | University of LouisvilleOTHER | 1 | May 2, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 26, 2024source: clinicaltrials